Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, VER-01, a full-spectrum cannabis extract, was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to approximately one year. The trial design meets the highest standard of clinical evidence, making its findings directly relevant to patients and clinicians considering cannabis-based options for a condition where existing medications frequently fall short.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally with inadequate pharmacologic options. The study’s design, including a 12-week double-blind phase and 6-month extension, enables assessment of both short-term efficacy and long-term safety, which are essential for establishing cannabis as a viable therapeutic option in standard pain management protocols. Given the opioid-related morbidity and limited effectiveness of current CLBP treatments, demonstration of efficacy and safety for VER-01 could support expanded clinical use and inform evidence-based cannabinoid prescribing guidelines.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain addresses a genuine clinical need, given the limitations and risks of conventional analgesics, though several factors warrant careful interpretation before implementation. The study’s size and structure are encouraging, but the abstract truncation prevents assessment of critical outcomes including effect magnitude, safety signals, and whether benefits persisted or emerged only during the open-label extension, which can inflate apparent efficacy through unblinding bias and regression to the mean. Clinicians should request the full publication to evaluate primary outcome definitions, withdrawal rates between groups, and adverse event profiles, particularly given variable cannabinoid composition in full-spectrum products and individual patient variability in metabolism and response. Until complete data are available, this trial may inform but should not yet anchor clinical decision-making, especially for patients with comorbid substance use history or those taking medications with significant cannabinoid interactions. If the data ultimately demonstrate meaningful, durable benefit with an acceptable safety profile, such extracts could offer a valuable option for select